The C-Suite: Mick Farrell, ResMed CEO
Medical equipment maker ResMed (RMD) reported a 9% rise in revenue for the June quarter, coming in at US$1.2 billion for the June quarter. Earnings came in at $1.98 a share in the period.
With 2.5 billion people suffering from sleep, health and breathing disorders, ResMed CEO Mick Farrell, Chief Executive remains optimistic. Saying RMD is well positioned to drive market penetration and accelerate growth for the business. Despite the positive outlook, shares have been under pressure this year amid concerns rapid weight loss drugs in the market will hurt demand for its products.